Barclays Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $67
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Equal-Weight rating on CRISPR Therapeutics (CRSP) and lowers the price target from $80 to $67.
May 09, 2024 | 2:50 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays maintains an Equal-Weight rating on CRISPR Therapeutics and lowers the price target from $80 to $67.
The reduction in price target by Barclays, a major financial institution, could lead to a negative short-term sentiment among investors, potentially causing a decrease in CRSP's stock price. The Equal-Weight rating suggests that the stock is adequately valued at its current price, but the lowered price target indicates that Barclays sees less upside potential than before.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100